2024 annual financial data
BioCryst Pharmaceuticals 2024 Operating margin
BioCryst Pharmaceuticals 2024 operating margin with verified reported values.
Direct answer
Operating margin was -0.56%.
Operating income was -2,543,000 USD and net income was -88,881,000 USD.
Operating cash flow was -52,020,000 USD.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 450,712,000 USD
- Operating income
- -2,543,000 USD
- Net income
- -88,881,000 USD
- Operating cash flow
- -52,020,000 USD